中国医药科学2024，Vol.14Issue(14)：151-154,198,5.DOI:10.20116/j.issn2095-0616.2024.14.36
PEG-rhG-CSF和rhG-CSF治疗化疗后中性粒细胞减少症的荟萃分析
Meta-analysis of PEG-rhG-CSF and rhG-CSF in the treatment of chemotherapy-induced neutropenia
摘要
Abstract
Objective Pegylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF)and recombinant human granulocyte colony stimulating factor(rhG-CSF)are the main drugs in the treatment of chemotherapy-induced neutropenia(CIN)for malignant tumors.In order to comprehensively evaluate the differences in efficacy and adverse reactions between them,it is necessary to analyze the existing experimental studies on them to better guide the clinic.Methods Chinese and English articles published in PubMed,Embase,Web of Science and China BioMedical Literature Database from June 2005 to June 2023 were searched.Results Nine randomized controlled studies were compared.The results showed that there was no significant difference in the incidence of CIN between patients receiving PEG-rhG-CSF treatment and rhG-CSF treatment(n=695,RR=0.49,95％CI[0.24,1.02],P=0.06),suggesting that the two treatments were equivalent.There was a significant difference in the incidence of adverse reactions between the two groups(n=695,RR=0.66,95％CI[0.55,0.78],P＜0.000 01).The reliability of the two treatments was good,and there was no publication bias and heterogeneity,Egger's results were(95％CI[5.56,2.45],P=0.390)and(95％CI[3.24,1.81],P=0.532).Conclusion PEG-rhG-CSF and rhG-CSF have equivalent efficacy,but PEG-rhG-CSF is significantly lower than rhG-CSF in the incidence of adverse reactions.关键词
聚乙二醇化重组人粒细胞集落刺激因子/重组人粒细胞集落刺激因子/化疗/中性粒细胞减少症Key words
PEG-rhG-CSF/rhG-CSF/Chemotherapy/Neutropenia分类
医药卫生引用本文复制引用
曹尚美,陈泊霖,杨少哲,张欢欢,邹真真,付秀虹..PEG-rhG-CSF和rhG-CSF治疗化疗后中性粒细胞减少症的荟萃分析[J].中国医药科学,2024,14(14):151-154,198,5.基金项目
河南省自然科学基金(2223000420247) （2223000420247）
河南省中央引导地方科技发展资金项目(Z20221343023) （Z20221343023）
河南省医学科技攻关项目(LHGJ20221031). （LHGJ20221031）
